Description
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subjects Who Require Red Blood Cell Transfusions
Contact Persn: James Nasman
Please contact NasmanJ@sutterhealth.org about study Commands
View study details on ClinicalTrials.govPrincipal Investigator
Oleg I. Krijanovski, M.D., Ph.D.
Co-Investigator(s)
Recruitment Status
Active, Recruiting
Start Date
March 18, 2020